Jpmorgan Chase & CO Entrada Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 10,812 shares of TRDA stock, worth $189,858. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,812
Previous 10,570
2.29%
Holding current value
$189,858
Previous $150,000
14.67%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding TRDA
# of Institutions
101Shares Held
28.1MCall Options Held
34.5KPut Options Held
16.4K-
Baker Bros. Advisors LP New York, NY4.87MShares$85.4 Million0.83% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$77.7 Million48.7% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$77.4 Million28.09% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.05MShares$53.6 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X01.71MShares$30.1 Million0.01% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $551M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...